CellCentric
CellCentric Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer therapeutic products. Established in 2003, the company specializes in small-molecule inhibitors that target p300 and CBP proteins, as well as a deubiquitinase enzyme closely linked to prostate cancer. This enzyme modulates the androgen receptor pathway, which is critical in addressing resistance mechanisms encountered with existing prostate cancer treatments. CellCentric's therapies aim to treat various cancers, including castrate-resistant prostate cancer, lung cancer, bladder cancer, non-small cell lung cancer, breast cancer, and colon cancer. By targeting specific pathways and mechanisms, CellCentric seeks to provide effective treatment options for patients with challenging cancer types.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.